Heron Therapeutics (HRTX) EBITDA (2010 - 2026)

Heron Therapeutics (HRTX) has reported EBITDA for 17 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 24.86% year-over-year to -$2.0 million; the trailing twelve-month figure through Jun 2026 stood at -$10.9 million (down 981.82% YoY), and the FY2025 full-year result was -$2.5 million, up 77.98% from the prior year.
• EBITDA grew to -$2.0 million in Q2 2026 per HRTX's latest filing, from -$4.8 million in the prior quarter.
• Across five years, EBITDA topped out at $4.2 million in Q4 2024 and bottomed at -$62.9 million in Q1 2022.
• Historically, EBITDA has averaged -$17.0 million across 5 years, with a median of -$5.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: EBITDA soared 165.74% in 2025, then plunged 251.08% in 2026.
• Over 5 years, EBITDA stood at -$20.4 million in 2022, then jumped by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then slumped by 99.09% to $38000.0 in 2025, then plunged by 5478.95% to -$2.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.0 million, -$4.8 million, and $38000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.